Stock Movers: Keurig Dr Pepper, Carter's, and Avidity Biosciences Updates

Keurig Dr Pepper's Financial Outlook

• 📈 Keurig Dr Pepper (KDP) shares rose after announcing an improved fiscal 2025 constant currency net sales growth outlook, now expected in a high-single-digit range.
• 💰 The company is raising $7 billion from Apollo and KKR to finance its acquisition of JDE Peet’s NV, aiming to alleviate investor concerns about debt.
• ☕ US coffee sales, which had previously declined, saw a 1.5% growth, indicating a positive shift.
• 🏢 KDP plans to separate its beverage and coffee businesses by the end of 2026.

Carter's Business Adjustments

• 📉 Carter's (CRI) shares fell as third-quarter net sales missed analyst estimates.
• ⚠️ The company anticipates a pre-tax earnings impact of $200 million to $250 million annually due to additional tariffs.
• 🛍️ Carter's plans to close approximately 150 stores in North America over the next three years, an increase from the previous target of 100.
• 🧑‍💼 A reduction of about 15% in office-based roles (around 300 positions) is planned, expected to yield $35 million in annual savings.

Avidity Biosciences Acquisition

• 🚀 Avidity Biosciences (RNA) shares surged significantly following the announcement that Novartis will acquire the company for $12 billion.
• 🤝 This acquisition is Novartis' largest in over a decade and aims to bolster its portfolio as generic competition looms for its current top-selling drugs.
• 💊 Novartis expects two to three Avidity drugs to launch before 2030, with multi-billion dollar sales potential.
• 🧬 Avidity will separate its early-stage cardiology programs into a new entity as part of the deal.
• 💡 The biotech sector is seeing a trend of large pharmaceutical companies acquiring smaller drug makers with innovative technologies to boost revenue.